Pfizer Trazimera [legacy through FY23] by Year

Name: Pfizer Trazimera [legacy through FY23] by Year (PFE)
Creator: Pfizer

Trazimera (trastuzumab biosimilar) [legacy through FY23] — Worldwide revenues ($M) ($M)

Quarterly Annual

Pfizer Trazimera [legacy through FY23]: $33M in FY2023, down 10.8% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2023

Period ended Dec 31, 2023

Change on a year earlier

-10.8%

37 in FY2022

History

5 years

Since FY2019

Sources

Documents cited below

Where the FY2023 figure comes from

“|| Trazimera | 33 | 37 | (11%) | (11%) | 8 | 8 | 6% | 12% | 57 | 51 | 11% | 21%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Trazimera (trastuzumab biosimilar) [legacy through FY23] — Worldwide revenues ($M) ($M)	Year on year	Source
FY2023	Dec 31, 2023	33	-10.8%	Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2022	Dec 31, 2022	37	-19.6%	Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2021	Dec 31, 2021	46	+53.3%	Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
FY2020	Dec 31, 2020	30	+400.0%	Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
FY2019	Dec 31, 2019	6	–	Form 10-K (filed 2022-02-24) ↗

Breakdown

What makes up trazimera [legacy through FY23]

Cite this data

StockData. (2026). Pfizer Trazimera [legacy through FY23] ($M), annual FY2019–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/trazimera-leg-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.